Valeant Pharmaceuticals International (VRX) Shares Down 1.5%

Shares of Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) were down 1.5% during mid-day trading on Wednesday . The stock traded as low as C$22.04 and last traded at C$22.53. Approximately 2,033,666 shares traded hands during mid-day trading, an increase of 40% from the average daily volume of 1,451,591 shares. The stock had previously closed at C$22.20.

Several analysts have issued reports on VRX shares. TD Securities raised Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price target on the stock in a research note on Wednesday, November 8th. Royal Bank Of Canada reissued a “sector perform” rating and issued a C$23.00 price target on shares of Valeant Pharmaceuticals International in a research note on Wednesday, November 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and a consensus price target of C$22.50.

In other news, Director Schutter Richard Urbain De purchased 10,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were purchased at an average price of C$14.33 per share, with a total value of C$143,300.00.

TRADEMARK VIOLATION WARNING: This report was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://weekherald.com/2017/12/06/valeant-pharmaceuticals-international-vrx-shares-down-1-5.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply